DOCSLIB.ORG

Author Index SOFT 2009 Bold Type

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index SOFT 2009 Bold Type Author Index SOFT 2009 A C Abbott, Lenox B. S29 Calverley, Richard P20, P40, P41 Agrawal, Alpana P21 Campognone, Michael P22, P23 Aiken, M. Jeannette S1 Canfield, Dennis V. S36 Alford, Ilene S35 Caplan, Yale H. S32, P67 Alkass, Kanar S31 Castro, Catherine P9, P12 Almazan, Perla P39 Catbagan, Philip P69 Alvarez, Lyvia A. P78 Caulfield, Joanna P20, P40, P41 Ananias, Davina P1, P2, P3, P4, P5 Cawthon, Beverly S32, P67 Andrenyak, David M. S10 Chang, Ning P59 Anne, Lakshmi P45 Charlebois, Rita C. S34 Annoni, Jean-Marie S12 Chavez, Carlos P78 Antonides, Heather M. S17 Chen, Bud-Gen P7 Appenzeller, Monique S12 Chi, Eric P84 Apple, Fred S. P56 Choo, Robin E. S3 Askwith, Joanna P26 Chronister, Chris W. P53 Aurand, Craig P70 Clark, Chantry J. S19, P18 Cochran, Jack S14, S15, P37 B Cole, Jason P84 Backer, Ronald P8 Collins, Ayodele P8 Baker, Eric S33 Concheiro, Marta S22 Baker, Ginger P71 Cone, Edward J. S32, P6, P67 Ballard, Kevin P33 Conte, Maria S. P19, P78 Barhate, Rehka S13, S25, P69, P77 Cooper, Gail S4 Barnes, Allan J. S5, S24 Corbett, Michael R. S34 Battistella, Giovanni S12 Cortes, Francisco P78 Baylor, Michael R. S23, P64 Coulter, Cynthia S25, P9, P10, P11, P12, P13, Behonick, George S. P55 P69, P77, P82 Benchikh, E.O. P72 Counter, Cynthia S6 Bendel, Olof S31 Countryman, Sky P22, P23, P46 Beno, Jeanne S33 Coyer, Michael J. P29 Binkley, Joe P66 Crespo, Edwin P78 Blacik, Larry S28 Crews, Bridgit P39 Black, David L. S32, P67 Crompton, Katherine P82 Blum, Kristen P1, P2, P3, P4, P5, P6, Crooks,C.Richard S20 P16 Bodepudi, Vani P38, P45 D Botch, Sabra R. P44, P50 Bourland, James P8, P62 Dahn, Tim P26 Brewer, William E. S18 Dalrymple, Robert P32 Brown, C. Sue S20 Dams, Riet S3 P24 Brunet, Bertrand R. S3 Danaceau, Jonathan Buclin, Thierry S12 Davila, Francisco P19, P78 Bui, H.M. P17 Davis, Rebecka P18 Burian, Dennis P52, P63, P81 DeLorenzo, Richard P63 Bush, Donna M P64 Dementieva, Yulia P76 Bynum, Nichole S2 Denson, Deborah J. P64 Desbrow, Claire P20, P40, P41 Desrosiers, Nathalie A. P47 Difeo, Dan P27, P28 DiGregorio, G.John S9 Bold type denotes presenting author. October, 2009 – Oklahoma City, OK Author Index SOFT 2009 Dilek, Isil P31, P59 H Dockery, Bryan P59 Hackett, Jeffery S37, P25, P29 Dowthwaite, Gary P20, P40, P41 Haggerty, Brenda P6 Druid, Henrik S31 Hart,E.Dale S23 Dubowski, Kurt M. S36 Hartman, Rebecca S33 Dudley, Mary P48 Harville, Don P63 Hassan, Huda S4 E He, Xiaowei S6 Eagerton, David H. P34 Heim, John P66 Elian, Albert A. S37, P25 Helka, Blake Joseph P60, P61 Ellefsen, Kayla N. P80 Heltsley, Rebecca S32, P67 Ellison, Sparkle T. S18 Helwig, Jessica S9 Ervin, Annette P32 Henderson, Brittney R. S34 Ervin, Joseph F. P26 Herreno, Diogenes P78 Esposito, Francis M. S23 Hickerson, Jeff S. P44, P50 Hoch, Daniel P3, P4 F Holzberg, Evan P30 Fahie, Kisha P51 Homan, Joseph P32 Favrat, Bernard S12 Huang, Mei-Han P42, P68 Fernandez, Christopher P46 Huestis, Marilyn A. S3, S5, S22, S24, P14, Fitzgerald, S.P. S26, P72, P73 P15 Fleming, Steven P48, P65 Hughes, John S19 Fontz, Mike P57 Hurt, C. P16 Fornari, Eleonora S12 Huynh, Kim S13, S25, P69, P77 Foster, Fred D. S18 Hwang, Rong-Jen P71 Fowler, David P51 Frazee, C. Clinton, III P48, P65 I Freeman, Robert P27, P28 Isoherranen, Nina S8 Fritch, Dean P1, P2, P3, P4, P5, P6, P16 J P49 Fuller, Dwain C. Janer, Jeanette P19, P78 Jenkins, Amanda J. S11 G Jenkins, Marita P63 Gairloch, Elena P20, P40, P41 Jenner, Jennifer L. P55 Garg, Uttam P48, P65 Jian, Huahua P31, P59 Garn, Joshua V. P18 Johnson, Derrell P31 Gates, Kevin P59 Johnson, Robert D. P44, P50 Geiselhart, Roberta P56 Johnson, Ted D. S29 Gesseck, Ashley P62 Jones, Hendree E. S3 Gines, Leric P45 Jones, Rhys P20, P40, P41 S12 Giroud, Christian Jordan, Steve P20, P40, P41 Goldberger, Bruce A. P53 Juenke, JoEtta M. P75 Goodwin, Robert S. S24 Jufer, Rebecca P51 Gooley, H.J. Andrew P27, P28 Juhascik, Matthew P. S11 Gorelick, David A. S24 Jurgen-Wirth, Hans P27, P28 Gray, Teresa R. S3, S22 Guan, Hongxia S18 Gunn, Joshua P70 Bold type denotes presenting author. October, 2009 – Oklahoma City, OK Author Index SOFT 2009 K Marinetti, Laureen J. S17, P58 Kacinko, Sherri P32 Martinez, Afton L. P71 Kane, Pete P55 Mazur, Frank P55 Kardos, Keith P1, P2, P3, P4, P5, Mazzanti Puff, Heather S9 P16 McAleer, D. P73 S5, Karschner, Erin L. P14 McConnell, R.I. S26, P72, P73 Kelly F.M. P73 McDonough, Pamela C. P83 Kelly, Deanna L. S24 McKinnon, Tracy A. P34 Kelly, Kory P46 McMillin, Gwendolyn A. S19. P18, P75 P70 Kennedy, Joseph H. McQuade, John P63 P17 Klette, K.L. Meatherall, Robert P54 Kloss, Julie P56 Melendez, Margarita P19 Knight, Laura P48 Merrell, Miles S19, P18, P75 Koerner, Philip P22 Merves, Michele L. P53 Kraner, James C. P76 Middleton, Owen P56 Kronstrand, Robert S31 Miethke, M. P16 Kuo, Jiann-Jyh P42 Mikel, Charles P39 P52, Kupfer, Doris M. P63 Miller, Eleanor I. P21, P35 Kurz, G. P16 Mills, Kelly M. P56 Milman, Garry S24, P14 L Mitchell, John M S23, P64 P33 Labay, Laura Mitra, Swati P45 Lan, Yu-Hsin P7 Moody, David S10 Latyshev, Sergey P39 Moore, Christine S6, P9, P10, P11, P13, Lauer, Estelle S12 P21, P69 Laughlin, Brian C. P70 Morales, Kelvin P19, P78 Lawrence, Christopher P4, P5, P16 Morehead, Rick S14 Lee, Steven P1, P2, P3, P4, P5, Morgan, Stephen L. S18 P16 Moser, Frank S32, P67 P83 Levine, Barry P51. Muehlbauer, M. P16 P53 Lewis, Jennifer N. Murray, Gordon J. P24 Lewis, Russell J. S36 Lichman, Aron H. P43 N S38 Liddicoat, Laura J. Naso, Clare P51 Lin, Ching-Chiang P68 Nemeth, Donna S33 Lin, Dong-Liang P7, P42 Nguyen, Loan P33 Liu, Hsiu-Chuan P7, P42 Nonnemacher, Sheena P6 Liu, Ray H. P7, P42, P68 Norris, Hye-Ryun K. P21, P35 S6 Liu, Xiaoyun Ntamack, Andre G. S28 Lo, Chih-Yu P68 Logan, Barry K. S39, P32 O Long, Kelly A. P43 O'Brien, Megan S9 Lowe, Ross H. S5 Oles, Monique A. P55 Lowry, P. S26, P72 Olson, Kalen N. P56 Luckenbill, Kristin P56 M Maeder, Philippe S12 Mall, Jean-Frederic S12 Mangin, Patrice S12 Marin, Stephanie J. S19, P18, P75 Bold type denotes presenting author. October, 2009 – Oklahoma City, OK Author Index SOFT 2009 P S Papa, Vincent M. P57 Sakuma, Takeo S15, P37 Past, Marilyn R. P83 Sample, R.H. Barry S29 Peat, Judy P65 Sanabria, Dario P78 Peng, James P79 Sanchez, Carl P22 Peng, Qiyuan P79 Sander, Lane P36 Perez, Jose L. P19 Sanford, Richard P30 Pesce, Amadeo P39 Sasaki, Tania S16 Peterson, Brianna L. S40 Scancella, J. P17 Phinney, Karen W. P36 Scarafile, Amy P57 Piper, Mark S26, P72, P73 Scheidweiler, Karl B. S5 Pisana, Patricia P49 Schreiber, Andre S15, S16, P37 Plant, Steve P20, P40, P41 Schueler, Harold P79 Pleitez, Oscar S7 Schwilke, Eugene W. S24 Pogue, Sherri P31 Schwope, David M. P14 Poklis, Alphonse S1, P43, P62 Scott-Ham, Michael S30 Poklis, Justin L. P43 Seldén, Tor S31 Prendergast, Jocelyn L. P36 Serrano, Javier G. P78 Primerano, Donald A. P76 Shakleya, Diaa M. S22, P15 Shan, Xiaoqin S35 Q Silva, Krystal P59 Quimby, Bruce D. P74 Silva-Torres, Luz A. P19, P78 Simons, Brian P58 R Smith, Dustin W. P34 Rajotte, James W. P61 Smyth, S. S26 Rana, Sumandeep S27 Soares, James S6, S13, S25, P69, Rankin, Gary O. P76 P77 Rashid, Shaker P2 Soriano, Glenda P1 Rasmussen, Natalie P75 Souffrant, Claudele P78 Ratcliffe, P. S26 Spayd, Stephanie S9 P59 Rettinger, Mitzi P59 Sreenivasan, Uma P31, Richards-Waugh, Lauren P76 Stajic, Marina P30 Rieders, Michael S9 Stall, Justin P1, P2, P3, P4, P5 Rigdon, Amanda S14, S15, P37 Staub, Christian S12 Ritter, Roxane M. S36 Stoppacher, Robert P33 Rivera Irma P78 Stout, Peter R. S23 Robandt, P.V. P17 Su, Lien-Wen P7, P42 Robert, Tim S32, P67 Sullivan, Matthew P6 Rodrigues, Rosa P78 Sutheimer, Craig A. P64 Rodrigues, Warren S13, S25, P69, P77 Swofford, Henry P57 Rodriguez, Edda L. P78 Rollins, Douglas E. P21, P35 Romberg, Robert W. S28 Ross, Wayne B. S27 Rummel, Michael P23 Ruzicka, Raimund P38, P45 Bold type denotes presenting author. October, 2009 – Oklahoma City, OK Author Index SOFT 2009 T Y Taruc, Margaux P9, P10, P11, P13 Yang, Liansheng S6 Telepchak, Michael J. P29 Yang, Shu-Ching P42 Terrell, Andrea P26 Ybarra, Sandra P31 Thammavong, Jerdravee S10 Yeakel, Jillian S9 Thatcher, Jayne E. S8 Yeatman, Dustin T. S35 Thomas, Aurelien S12 Yoder, Kathryn P1, P2, P3, P4, P5 Thompson, Candace C. P43 Young, Thomas P48 Thompson, Jonathan P56 Tiffany, Stephen T. P21, P35 Z Tiscione, Nicholas S35 Zelter, Alex S8 Tormos, Lee M P78 Zhang, Rong P38 Torres, Jose V. P19, P78 Zhao, Yuhong P1, P2, P3, P4 Trass, Matthew P23 Zichterman, Anne S32, P67 Tuyay, James P9, P10, P11, P13 V Vazquez, Emilirma P78 Vincent, Michael S6, S13, S25, P21, P69, P77, P82 Vollmerhaus, Pauline S16 Vorce, Shawn P. P83 W Wahba, Wagdy W. S21 Wallace, Frank N. P64 Wang, Guohong S6, S13, S25, P69, P77 Wang, Sang-Jang P68 Wang, Yu-Shan P7, P42 Watterson, James H. P47, P60, P61, P80 Weier, G. P16 Weindel, K. P16 Welsh, Eric R. S28 West, Christopher P5 West, Robert P39 Whinnery, James E. S36 White, Candyce P81 White, Vicky L. P52, P63, P81 Wilkins, Diana G. P21, P35 Williams, Lee P20, P40, P41 Willson, Savannah P81 Wiseman, Justin M. P70 Wittrig, Rebecca S14, S15, P37 Wolf, Carl E. S1, P62 Woods, Howard P1, P3 Wu, Hung-Chi P68 Wu, Meng-Yan P7, P68 Wynne, Paul P27, P28 Bold type denotes presenting author.
Load more

Recommended publications
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Antidepressants
    Antidepressants BMF 83 - Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals 1 in the brain, namely serotonin and noradrenaline . Everyone experiences highs and lows, but depression is characterised by 2 persistent sadness for weeks or months . With depression there is lasting feeling of hopelessness, often accompanied by anxiety. Sufferers lose interest in things that they previously enjoyed, and experience bouts of tearfulness. Rational thinking and decision 2 making are impacted. Physical manifestations include tiredness, insomnia, loss of appetite and sex drive, aches and pains . At its worst depression can cause the sufferer to feel suicidal. Depression is usually treated with a combination of counselling and drug therapy. There is also evidence that exercise can help depression. Most people with moderate or severe depression benefit from antidepressant medication. There are a wide range of 3 antidepressants on the market, which can be broadly divided according to mechanism of action ; • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Serotonin modulator and stimulators (SMSs) • Serotonin antagonist and reuptake inhibitors (SARIs) • Norepinephrine reuptake inhibitors (NRIs or NERIs) • Tetracyclic antidepressants (TeCAs) • Tricyclic antidepressants (TCAs) • Monoamine oxidase inhibitors (MAOIs) www.chiron.no | E-mail: [email protected] | Tel.: +47 73 87 44 90 | Fax.: +47 73 73 87 44 99 | BMF 83 p.1/8 , 10_16 BMF 83 - Antidepressants BMF 83 - Antidepressants 1 Today the most common first choice of medication is a SSRI , i.e. Citalopram, Escitalopram, Fluvoxamine, Paroxetine, Sertraline, Fluoxetine. Antidepressants are not addictive, but can result in withdrawal symptoms when therapy is stopped.
    [Show full text]
  • 2016-11-BMF-83 Antidepressants
    Antidepressants BMF 83 - Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals 1 in the brain, namely serotonin and noradrenaline . Everyone experiences highs and lows, but depression is characterised by 2 persistent sadness for weeks or months . With depression there is lasting feeling of hopelessness, often accompanied by anxiety. Sufferers lose interest in things that they previously enjoyed, and experience bouts of tearfulness. Rational thinking and decision 2 making are impacted. Physical manifestations include tiredness, insomnia, loss of appetite and sex drive, aches and pains . At its worst depression can cause the sufferer to feel suicidal. Depression is usually treated with a combination of counselling and drug therapy. There is also evidence that exercise can help depression. Most people with moderate or severe depression benefit from antidepressant medication. There are a wide range of 3 antidepressants on the market, which can be broadly divided according to mechanism of action ; • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Serotonin modulator and stimulators (SMSs) • Serotonin antagonist and reuptake inhibitors (SARIs) • Norepinephrine reuptake inhibitors (NRIs or NERIs) • Tetracyclic antidepressants (TeCAs) • Tricyclic antidepressants (TCAs) • Monoamine oxidase inhibitors (MAOIs) www.chiron.no | E-mail: [email protected] | Tel.: +47 73 87 44 90 | Fax.: +47 73 73 87 44 99 | BMF 83 p.1/8 , 10_16 BMF 83 - Antidepressants BMF 83 - Antidepressants 1 Today the most common first choice of medication is a SSRI , i.e. Citalopram, Escitalopram, Fluvoxamine, Paroxetine, Sertraline, Fluoxetine. Antidepressants are not addictive, but can result in withdrawal symptoms when therapy is stopped.
    [Show full text]
  • An Update on Therapeutic Drug Monitoring and Pharmacogenetic Testing for the Optimization of Therapy with Psychiatric Medication
    J Lab Med 2014; aop Review Katharina M. Rentsch* An update on therapeutic drug monitoring and pharmacogenetic testing for the optimization of therapy with psychiatric medication DOI 10.1515/labmed-2014-0032 Keywords: antidepressants; antipsychotic drugs; cyto- Received September 28, 2013; accepted January 28, 2014 chrome; pharmacogenetics; psychiatric medication. Abstract: Therapeutic drug monitoring of psychiatric medication as well as pharmacogenetic testing is per- formed more and more frequently in numerous labora- Introduction tories. In this review, a summary of the literature in the years 2011 and 2012 has been completed. The guidelines The Therapeutic Drug Monitoring (TDM) of psychophar- of the German AGNP (Association for Neuropsychop- maceutical drugs is carried out in numerous laboratories harmacology and Pharmacopsychiatry) contain all the to an ever more frequent extent, as are pharmacogenetic information needed for the interpretation of drug concen- studies. Based on numerous studies that have shown that trations. The determination of serotonin in urine could pharmacogenetic polymorphisms, among other factors, be a marker for the assessment of the response of antide- cause large inter-individual differences in the pharma- pressants, and correlations between the occupancy of the cokinetics of psychopharmaceutical drugs, doctors who target receptors in the brain and drug concentration have prescribe such drugs increasingly order TDM tests. As part been established using positron emission tomography. of the diagnostics updates 2013 [1] a compilation of the The influence of age on drug concentrations has been literature on the above topics published in 2011 and 2012 controversially described, and additionally females have was prepared, and the individual papers and studies were always showed a slower metabolism and higher serum evaluated.
    [Show full text]
  • Method Validation of a Tricyclic Antidepressant Drug Panel in Urine by LC-MS/MS
    Method Validation of a Tricyclic Antidepressant Drug Panel in Urine by LC-MS/MS Chia-Ni Lin, 1 JoEtta M. Juenke, 2 and Kamisha L. Johnson –Davis1,2. 1Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT USA, 2ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT USA Introduction Imprecision Method Comparison Tricyclic antidepressants (TCA) can cause serious cardiac complications and Imprecision was determined by analyzing three levels of control material To evaluate accuracy, drug-free urine was pooled and used as a matrix to spike 22 samples with TCA at can be lethal if misused at high doses; as a result, TCA should be monitored. To prepared in quintuplicate at five concentrations for five days (n = 25 for each different concentrations. An additional 33 patient samples were collected and sent to an alternate monitor patient compliance to therapy, urine specimens may be preferred since concentration). laboratory for split sample comparison by gas chromatography-mass spectrometry (GC/MS). Out of a total the collection is non-invasive and the specimen can provide a longer detection of 55 results, there were three false negative results for nortriptyline and two false negative results for window. TCA are frequently monitored by immunoassay; however false Expected Mean Within Run Between Day Total amitriptyline, when compared to compared GC/MS method. The false negative results could be due to the positives and cross reactivity to other cyclic compounds may compromise Drug Sample N (ng/mL) (ng/mL) SD CV (%) SD CV (%) SD CV (%) different sample preparations and positive cut-off concentrations between the two laboratories.
    [Show full text]
  • TOX.LC.3499 Rev 07, Effective 2015-08-12 to Present
    Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: LC & LCMSMS Procedure No.: TOX.LC.3499 Title: Amitriptyline, Clozapine, Doxepin, Fluoxetine, Quetiapine and Olanzapine Rev.7 (LLE) by LCMSMS 1.0 Purpose 1.1 Amitriptyline, Nortriptyline, Clozapine, Doxepin, Nordoxepin (Desmethyldoxepin), Fluoxetine, Norfluoxetine, Quetiapine, Norquetiapine, and Olanzapine are assayed by High Performance Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (HPLC/MS/MS) using multiple reaction monitoring (MRM) and their corresponding deuterated standards. 2.0 Scope 2.1 The analysis is applicable to all types of forensic specimens when compared with matrix matched controls. 3.0 Definitions and Abbreviations 3.1 None Applicable 4.0 Materials 4.1 Instruments and Equipment 4.1.1 Pipettes 4.1.2 13 x 100 mm screw cap test tubes 4.1.3 16 x 100 mm test tubes 4.1.4 Vortex mixer 4.1.5 Centrifuge 4.1.6 Autosampler vials 4.1.7 Vial caps with puncture seals 4.1.8 Solvent evaporator 4.1.9 Nitrogen compressed gas 4.1.10 0.2 m Filters 4.1.11 3 c.c. Syringe 4.1.12 C18 PLC column 4.1.13 LC-MS/MS 4.2 Reagents 4.2.1 Methanol, HPLC grade 4.2.2 n-Butyl Chloride, HPLC grade 4.2.3 Acetonitrile, HPLC grade 4.2.4 Formic Acid 88% 4.2.5 Water, 18.2 mega ohm or HPLC grade 4.2.6 Ammonium formate. Page 1 of 12 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: LC & LCMSMS Procedure No.: TOX.LC.3499 Title: Amitriptyline, Clozapine, Doxepin, Fluoxetine, Quetiapine and Olanzapine Rev.7 (LLE) by LCMSMS 4.2.7 Saturated Sodium Borate Buffer A.
    [Show full text]
  • Complete Article
    _J Clin Pathol 1999;52:713-718 713 Leader Detection of drug misuse an addictive challenge. John H Galloway, Ian D Marsh Abstract base: "crack"). In addition to these illicit It is now accepted that drug misuse is a compounds various drugs intended for medical large and growing problem in the United use have been "adopted" into misuse. In Kingdom, some estimates of the number particular the benzodiazepines (diazepam and of regular illicit drug users being as high temazepam) are widely misused, as are opiates as three million. The aim of this paper is including diamorphine (heroin) and dihydroco- to provide insight into the methods used to deine. Ketamine, methadone, tricyclic antide- detect drug misuse. The strategy adopted pressants, and dextropropoxyphene are further by one laboratory is described and meth- examples of prescribed drugs encountered in ods of screening for, and identification of, individuals who have not been prescribed them. a wide range of compounds are provided. The casual use of these drugs may never be a No claim is made that this is the best problem and is, for many, a natural part of rec- approach or that the list of drugs detected reational activity. The use of these drugs is comprehensive; the range of drugs becomes a problem only if the individual encountered is always increasing and the involved becomes a habitual user and suffers lists are constantly updated. It is hoped longer term physical problems (illness and that users of toxicology laboratory serv- infections) and psychological problems which ices will gain an appreciation of the capa- make them unable to be fully active and bilities and limitations of the techniques productive members of society.
    [Show full text]
  • Quantification of Tricyclic Antidepressants in Human Plasma Or Serum by LC-HRAM(MS) for Clinical Research
    TECHNICAL NOTE 73330 Quantification of tricyclic antidepressants in human plasma or serum by LC-HRAM(MS) for clinical research Authors: Claudio De Nardi1, Katharina Kern2, Steffen Peters2 1Thermo Fisher Scientific GmbH, Dreieich, Germany 2RECIPE Chemicals + Instruments GmbH, Munich, Germany Keywords: Tricyclic antidepressants, offline sample preparation, plasma, serum, Orbitrap, high-resolution mass spectrometry Application benefits • Increased accuracy of method by implementation of a comprehensive ClinMass® kit for sample preparation Goal Implementation of an analytical method for the • High-resolution mass spectrometry for improved quantification of 13 different tricyclic antidepressants selectivity in human plasma or serum on a Thermo Scientific™ ™ ™ • Robust, sensitive hardware enables increased Q Exactive Plus hybrid quadrupole-Orbitrap mass confidence in data spectrometer. • Simple offline sample preparation by protein precipitation Introduction Tricyclic antidepressants (TCAs) are commonly used • 13 tricyclic antidepressants in a single quantitative to treat depression, anxiety reactions, and neuropathic method pain, despite the risk of severe side effects. Monitoring serum concentrations of TCAs can assess suspected toxicity, and/or drug-drug interactions. High-pressure Plasma or serum samples were extracted by offline internal liquid chromatography (HPLC) with ultraviolet (UV) standard addition and protein precipitation. Extracted spectrophotometric detection has been the recommended samples were injected onto a Thermo Scientific™
    [Show full text]
  • Antidepressant Drugs-1
    Module: CNS Subject: Pharmacology Lecture: MBBS Antidepressant Drugs-1 Dr Biswadeep Das Assoc Prof(Pharmacology) Department of Pharmacology/AIIMS Rishikesh [email protected] Mental Depression… What is it ? What is Mental Depression ?-Mood Disorder Pleasure seeking = Hedonistic Inability to experience pleasure = Anhedonia Disorders of Mood (Affective Disorders) • Depression (unipolar depression) • Mania • Reactive depression (75%) • Endogenous depression (25%) • Manic-depression (bipolar depression) What are the possible mechanisms of depression ? • Depression is associated with insufficient central release of NE and 5-HT • Led to development of the Biogenic Amine Hypothesis Antidepressant Drugs-Classification n Tricyclic Agents ¨Imipramine/Desipramine/ Clomipramine/ Amitriptyline/Nortriptyline/ Protriptyline/Doxepin/ Nordoxepin Antidepressant Drugs-Classification (contd.) n Heterocyclic Agents ¨Unicyclic n Bupropion ¨Tetracyclic n Amoxapine(N-desmethyl loxapine)/Maprotilene/ Mirtazapine n 5-HT2 Antagonists ¨Nefazodone/Trazodone Antidepressant Drugs-Classification (contd.) n Mono-Amine-Oxidase-A Isozyme Inhibitors (MAO-AI’s) ¨Hydrazine group n Isocarboxazid/Phenelzine ¨Nonhydrazine group n Nialamide/Tranylcypromine/Clorgyline/Pargyline/ Moclobemide/Brofaromine/Cimoxatone/Toloxatone Selective Serotonin Reuptake Inhibitors (SSRI’s) n Selective Serotonin Reuptake Inhibitors (SSRI’s) ¨Citalopram/ Escitalopram/ Fluoxetine/ Paroxetine/ Sertraline/ Fluvoxamine Serotonin NE Reuptake Inhibitors (SNRI’s) n Serotonin Norepinephrine Reuptake
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH Pr SILENOR® Doxepin tablets 3 and 6 mg doxepin as doxepin hydrochloride Hypnotic Paladin Labs Inc. Date of Preparation: 6111 Royalmount Ave. December 07, 2012 Montreal, Quebec H4P 2T4 Version : 1.3 Submission Control No: 152398 ® Trademark of Pernix Therapeutics LLC. SILENOR Product Monograph Page 1 of 30 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................15 ACTION AND CLINICAL PHARMACOLOGY ............................................................17 STORAGE AND STABILITY ..........................................................................................19
    [Show full text]
  • Doxepin for Insomnia
    Out of the Pipeline p Doxepin for insomnia Dimitri Markov, MD, and Karl Doghramji, MD ow-dose doxepin—3 mg and 6 mg— Table 1 Low-dose doxepin has demonstrated efficacy for insom- may relieve sleep Doxepin: Fast facts Lnia characterized by frequent or early- maintenance morning awakenings and an inability to Brand name: Silenor insomnia and is return to sleep (Table 1).1 FDA-approved in Indication: Insomnia characterized by difficulty not designated March 2010, doxepin (3 mg and 6 mg) is only with sleep maintenance as a controlled the second insomnia medication not des- Approval date: March 2010 ignated as a controlled substance and thus Availability date: September 7, 2010 substance may be of special value in patients with a Manufacturer: Somaxon Pharmaceuticals history of substance abuse. Dosage forms: 3 mg and 6 mg tablets Recommended dosage: 3 mg or 6 mg once Clinical implications daily within 30 minutes of bedtime Ramelteon, the other hypnotic that is not a controlled substance, is indicated for sleep initiation insomnia (ie, inability to fall How it works asleep). In contrast, low-dose doxepin is for Doxepin’s mechanism of action for treat- patients with sleep maintenance insomnia, ing depression and insomnia remains un- which is waking up frequently or early in known. The antidepressant effect of dox- the morning and not falling back asleep.1,2 epin is thought to result from inhibition A tricyclic antidepressant first approved of serotonin and norepinephrine reuptake in 1969, doxepin has long been available in at the synaptic cleft. Animal studies have larger doses (10-, 25-, 50-, 75-, 100-, and 150- shown anticholinergic and antihistamin- mg capsules) to treat depression and anxiety ergic activity with doxepin.2 Doxepin and as a topical preparation (5% cream) for is a potent histamine antagonist—pre- pruritus, but not in dosages <10 mg.
    [Show full text]
  • Ascentis® ES Cyano HPLC Columns
    Ascentis® ES Cyano HPLC Columns Key Benefits Cyano columns have been used for the analysis of Tricyclic Antidepressants for some time. A comparison of the most popular competitor column and the Ascentis L Extra stable for low pH mobile phases due to sterically ES Cyano phase is shown below. Better resolution is seen using the Ascentis ES protected phase Cyano than the competitor column for three critical peak pairs. In addition, note the selectivity change of the trimipramine and doxepin (peaks 1 and 2) between these L Improved retention compared two phases under these conditions to other cyano phases L Endcapped for better peak shape at neutral pH Tricyclic Antidepressants on Ascentis ES Cyano and a Competitor Cyano Phase column: as indicated; 15 cm x 4.6 mm, 5 μm particle mobile phase A: 10 mM potassium phosphate, dibasic (pH 7.0 with phosphoric acid) mobile phase B: acetonitrile 1. Trimipramine mobile phase C: methanol 2. Doxepin mixing proportions: A:B:C, 25:60:15 3. Amitriptyline flow rate: 2.0 mL/min 4. Imipramine temp.: 25 °C 5. Nordoxepin det.: 215 nm 2 6. Nortriptyline injection: 5 μL Ascentis ES Cyano 7. Desipramine sample: 100 μg /mL in 70:30, 8. Protriptyline water: methanol 3 5 1 4 6 7 8 0 2 4 6 8 10 12 14 2 Min G004971 3 Competitor Cyano 1 5 4 6 7 8 02468101214 Min G004972 Trimipramine Doxepin Amitriptylin Imipramine G004973 G004974 G004975 G004976 Desipramine Nordoxepin Nortriptyline Protriptyline G004977 G004979 G004980 G004978 Extended Stability of Ascentis ES Cyano Compared to Traditional Cyano Columns using Acidic Mobile Phases 2.5 2.0 Ascentis ES Cyano 1.5 k’ Traditional Cyano 1.0 0.5 0 0102030405060 Void Volumes (x 1,000) G004981 Ascentis ES Cyano HPLC Columns Length (cm) ID (mm) Cat.
    [Show full text]